Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia

Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in patients with T2DM by increasing both α- and β-cell responsiveness to glucose. In earlier studies enrolling patients with T2DM and baseline A1C of 7.5 to 11%, vildagliptin 100mg daily was very well-tolerated and decreased mean A1C by 1% or more. However, despite current trends toward earlier and more aggressive intervention, patients with T2DM and only mild hyperglycemia are not well-studied. This 52-week, randomized study examined efficacy and tolerability of vildagliptin 50mg qd (n=156) vs. placebo (n=150) in patients with…